希少疾患遺伝子検査市場：疾患タイプ、技術、専門分野、エンドユーザー別-2025年～2030年の世界予測

希少疾患遺伝子検査市場は、2023年に13億3,000万米ドルと評価され、2024年には15億4,000万米ドルに達すると予測され、CAGR 16.15％で成長し、2030年には38億米ドルになると予測されています。

希少疾患遺伝子検査は、希少疾患の原因となる遺伝子変異を同定する診断検査であり、多くの場合、世界中に散らばる少数の患者集団に影響を与えます。この分野の必要性は、早期診断、個別化医療、特に従来の治療がうまくいかない場合に的を絞った治療の選択肢を提供する上で重要な役割を果たすことに起因します。遺伝子検査は主に臨床と研究の場で応用され、十分な情報に基づいた臨床判断、患者カウンセリング、医薬品開発をサポートし、その最終用途は病院、診断センター、研究機関に及ぶ。遺伝子検査の成長は、ゲノム配列決定技術の進歩、認知度の向上、希少疾病研究に対する政府の支援政策によってもたらされます。さらに、製薬企業への投資や診断企業との提携が増加していることも大きな成長機会となっています。コンパニオン診断と精密医療に対する需要の高まりは市場の可能性を増大させ、IT対応の遠隔医療ソリューションは検査へのアクセスを容易にします。

しかし、市場は高コスト、規制上の課題、遺伝子データのプライバシーをめぐる倫理的懸念、新興国地域での認知度の低さといった限界に直面しています。こうした課題を解決するには、戦略的な価格設定、規制の明確化、プライバシー保護の強化が必要です。イノベーションのホットスポットとしては、手頃な価格のシーケンス技術の開発、予測分析のためのAIの統合、データ解釈のための高度なバイオインフォマティクスツール、個別化デジタルヘルスプラットフォームなどが挙げられます。市場機会を活用するための主な推奨事項には、分子診断企業との協力関係の促進、ビッグデータ解析の活用、遺伝カウンセラーと患者の相互作用を強化する患者中心のソリューションの確立などがあります。この市場は研究集約的で専門性が高く、ゲノム科学や規制状況への深い理解が求められます。バイオテクノロジー、データアナリティクス、ヘルスケアの融合は、新規治療の道筋や革新的なケア経路を生み出すエコシステムを約束し、希少疾患管理におけるブレークスルーの道を開くとともに、市場の状況を破壊する可能性があります。規制やコストの課題を克服することで、企業はこの進化する分野におけるリーダーとしての地位を確立することができます。

市場力学：急速に進化する希少疾患遺伝子検査市場の主要市場インサイトを公開

希少疾患遺伝子検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 希少遺伝病の流行と早期・迅速診断の必要性
  • 新規変異の同定を目的としたトランスレーショナル＆ゲノム研究における利用の増加
  • 希少疾患の診断と治療に対する政府の取り組み
• 市場抑制要因
  • 倫理的懸念と希少疾患に関する限られた情報へのアクセス
• 市場機会
  • 新たな希少疾患遺伝子を同定するための遺伝子技術の進歩
  • 希少遺伝病診断のための有利な投資
• 市場の課題
  • 新しい希少疾患遺伝子検査の承認プロセスに関連する厳しい規制

ポーターの5つの力：希少疾患遺伝子検査市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：希少疾患遺伝子検査市場における外部からの影響の把握

外部マクロ環境要因は、希少疾患遺伝子検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析希少疾患遺伝子検査市場における競合情勢の把握

希少疾患遺伝子検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス希少疾患遺伝子検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、希少疾患遺伝子検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 希少遺伝性疾患の蔓延と早期かつ迅速な診断の必要性
    • 新たな変異の特定のためのトランスレーショナル研究およびゲノム調査における利用の増加
    • 希少疾患の診断と治療に関する政府の取り組み
  • 抑制要因
    • 希少疾患に関する倫理的懸念と限られた情報へのアクセス
  • 機会
    • 新たな希少疾患遺伝子を特定するための遺伝子技術の進歩
    • 希少遺伝性疾患の診断に対する有利な投資
  • 課題
    • 新たな希少疾患遺伝子検査の承認プロセスに関連する厳格な規制
• 市場セグメンテーション分析
  • 疾患タイプ：希少遺伝性疾患のスクリーニングニーズに応える高度な検査の開発
  • エンドユーザー：学術機関の調査室における希少遺伝子検査に関する新たな研究
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 希少疾患遺伝子検査市場：疾患タイプ別

• がん
• 心血管疾患
• 皮膚科疾患
• 内分泌・代謝疾患
• 血液疾患
• 免疫疾患
• 筋骨格障害
• 神経疾患

第7章 希少疾患遺伝子検査市場：技術別

• アレイテクノロジー
• 魚
• 核型分析
• 次世代シーケンシング
  • 全エクソーム配列解析
  • 全ゲノム配列解析
• PCRベースの検査
• サンガーシーケンス

第8章 希少疾患遺伝子検査市場：専門分野別

• 生化学的遺伝子検査
• 染色体遺伝子検査
• 分子遺伝学的検査

第9章 希少疾患遺伝子検査市場：エンドユーザー別

• 診断検査室
• 病院・クリニック
• 研究機関とCRO

第10章 南北アメリカの希少疾患遺伝子検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の希少疾患遺伝子検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの希少疾患遺伝子検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Burjeel Holdings、米国のBridgebio Pharmaと提携し希少疾患研究開発プロジェクト「Nader」を開始
  • NIH、正常なヒト細胞と組織における遺伝的変異の調査に1億4,000万米ドルの取り組みを開始
  • CENTOGENE、希少疾患および神経変性疾患の診断のための全ゲノムシーケンスソリューション、新しいCentoGenomeを発表

企業一覧

• Laboratory Corporation Of America Holdings
• Biora Therapeutics, Inc.
• 3billion, Inc.
• Caris Life Sciences
• Ambry Genetics Corporation
• OPKO Health, Inc.
• Color Health, Inc.
• Quest Diagnostics Incorporated
• Nonacus Limited
• Integrated DNA Technologies, Inc. by Danaher Corporation
• Myriad Genetics, Inc.
• Blueprint Genetics Oy
• PerkinElmer Inc.
• Macrogen, Inc.
• F. Hoffmann-La Roche Ltd.
• Variantyx, Inc.
• Centogene N.V.
• Fulgent Genetics, Inc.
• Genomelink, Inc.
• Illumina, Inc.
• GeneDx, LLC
• Invitae Corporation
• Sanofi S.A.
• Helix OpCo, LLC
• Arup Laboratories
• The Cooper Companies, Inc.
• QIAGEN N.V.
• Realm IDX, Inc.
• Baylor Genetics
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. RARE DISEASE GENETIC TESTING MARKET RESEARCH PROCESS
• FIGURE 2. RARE DISEASE GENETIC TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RARE DISEASE GENETIC TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. RARE DISEASE GENETIC TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DERMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ENDOCRINE & METABOLISM DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HEMATOLOGY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY ARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY FISH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY KARYOTYPING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PCR - BASED TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY BIOCHEMICAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY CHROMOSOMAL GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY MOLECULAR GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 52. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 53. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 54. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 80. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 81. CHINA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 85. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 86. INDIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 90. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 91. INDONESIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 95. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 96. JAPAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 100. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 101. MALAYSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 105. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 106. PHILIPPINES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 110. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 111. SINGAPORE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 115. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 116. SOUTH KOREA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 120. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 121. TAIWAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 125. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 126. THAILAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 130. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 131. VIETNAM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 141. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 142. DENMARK RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 146. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 147. EGYPT RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 151. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 152. FINLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 156. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 157. FRANCE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 161. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 162. GERMANY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 166. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 167. ISRAEL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 169. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 171. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 172. ITALY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 176. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 177. NETHERLANDS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 181. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 182. NIGERIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 186. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 187. NORWAY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 189. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 190. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 191. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 192. POLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 193. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 194. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 195. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 196. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 197. QATAR RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 201. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 202. RUSSIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 206. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 207. SAUDI ARABIA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 211. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 212. SOUTH AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 216. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 217. SPAIN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 221. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 222. SWEDEN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 226. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 227. SWITZERLAND RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 231. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 232. TURKEY RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 236. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 237. UNITED ARAB EMIRATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
• TABLE 241. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY SPECIALTY, 2018-2030 (USD MILLION)
• TABLE 242. UNITED KINGDOM RARE DISEASE GENETIC TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 244. RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Rare Disease Genetic Testing Market was valued at USD 1.33 billion in 2023, expected to reach USD 1.54 billion in 2024, and is projected to grow at a CAGR of 16.15%, to USD 3.80 billion by 2030.

Rare disease genetic testing involves diagnostic tests to identify gene mutations causing rare disorders, often affecting small patient populations scattered globally. This field's necessity stems from the critical role it plays in early diagnosis, personalized medicine, and providing targeted treatment options, especially when traditional therapies fail. Primarily applied in clinical and research settings, genetic testing supports informed clinical decisions, patient counseling, and drug development, with end-use scope spanning hospitals, diagnostic centers, and research institutes. The growth of genetic testing is driven by advances in genome sequencing technologies, increased awareness, and supportive government policies for rare disease research. Additionally, the increase in pharmaceutical investments and collaborations with diagnostic companies represents significant growth opportunities. A rise in demand for companion diagnostics and precision medicine amplifies market potential, while IT-enabled telehealth solutions ease testing accessibility.

However, the market faces limitations like high costs, regulatory challenges, ethical concerns around genetic data privacy, and limited awareness in developing regions. These challenges necessitate strategic pricing, clearer regulatory frameworks, and privacy protection advancements to foster market expansion. Innovation hotspots include the development of affordable sequencing technologies, integration of AI for predictive analytics, advanced bioinformatics tools for data interpretation, and personalized digital health platforms. Key recommendations to capitalize on market opportunities include fostering collaborations with molecular diagnostic firms, leveraging big data analytics, and establishing patient-centric solutions that enhance interaction between genetic counselors and patients. The nature of this market is research-intensive and highly specialized, requiring a keen understanding of genomic science and regulatory landscapes. The convergence of biotechnology, data analytics, and healthcare promises a generative ecosystem for novel therapeutic avenues and innovative care pathways, paving the way for breakthroughs in rare disease management and potentially disrupting the market landscape. By navigating regulatory and cost challenges, businesses can position themselves as leaders in this evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rare Disease Genetic Testing Market

The Rare Disease Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
  • Rising Use in Translational & Genomic Research for Identification of Novel Mutations
  • Government Initiatives for Diagnosis and Treatment of Rare Diseases
• Market Restraints
  • Ethical Concerns and Access to Limited Information on Rare Disease
• Market Opportunities
  • Advancements in Genetic Technology to Identify New Rare Disease Genes
  • Favorable Investments for Diagnosis of Rare Genetic Diseases
• Market Challenges
  • Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test

Porter's Five Forces: A Strategic Tool for Navigating the Rare Disease Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rare Disease Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rare Disease Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rare Disease Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rare Disease Genetic Testing Market

A detailed market share analysis in the Rare Disease Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rare Disease Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rare Disease Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Rare Disease Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Laboratory Corporation Of America Holdings, Biora Therapeutics, Inc., 3billion, Inc., Caris Life Sciences, Ambry Genetics Corporation, OPKO Health, Inc., Color Health, Inc., Quest Diagnostics Incorporated, Nonacus Limited, Integrated DNA Technologies, Inc. by Danaher Corporation, Myriad Genetics, Inc., Blueprint Genetics Oy, PerkinElmer Inc., Macrogen, Inc., F. Hoffmann-La Roche Ltd., Variantyx, Inc., Centogene N.V., Fulgent Genetics, Inc., Genomelink, Inc., Illumina, Inc., GeneDx, LLC, Invitae Corporation, Sanofi S.A., Helix OpCo, LLC, Arup Laboratories, The Cooper Companies, Inc., QIAGEN N.V., Realm IDX, Inc., Baylor Genetics, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Rare Disease Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Cancer, Cardiovascular Disorders, Dermatology Diseases, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
• Based on Technology, market is studied across Array Technology, FISH, Karyotyping, Next Generation Sequencing, PCR - Based Testing, and Sanger Sequencing. The Next Generation Sequencing is further studied across Whole Exome Sequencing and Whole Genome Sequencing.
• Based on Specialty, market is studied across Biochemical Genetic Tests, Chromosomal Genetic Tests, and Molecular Genetic Tests.
• Based on End-User, market is studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Prevalence of Rare Genetic Disease and Need for Early & Rapid Diagnosis
    • 5.1.1.2. Rising Use in Translational & Genomic Research for Identification of Novel Mutations
    • 5.1.1.3. Government Initiatives for Diagnosis and Treatment of Rare Diseases
  • 5.1.2. Restraints
    • 5.1.2.1. Ethical Concerns and Access to Limited Information on Rare Disease
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in Genetic Technology to Identify New Rare Disease Genes
    • 5.1.3.2. Favorable Investments for Diagnosis of Rare Genetic Diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulations Associated with the Approval Process of New Rare Diseases Genetic Test
• 5.2. Market Segmentation Analysis
  • 5.2.1. Disease Type: Development of advanced tests to cater to the screening needs of rare genetic diseases
  • 5.2.2. End-User: Emerging studies on rare genetic testing in research laboratories in academic institutes
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Rare Disease Genetic Testing Market, by Disease Type

• 6.1. Introduction
• 6.2. Cancer
• 6.3. Cardiovascular Disorders
• 6.4. Dermatology Diseases
• 6.5. Endocrine & Metabolism Diseases
• 6.6. Hematology Diseases
• 6.7. Immunological Disorders
• 6.8. Musculoskeletal Disorders
• 6.9. Neurological Disorders

7. Rare Disease Genetic Testing Market, by Technology

• 7.1. Introduction
• 7.2. Array Technology
• 7.3. FISH
• 7.4. Karyotyping
• 7.5. Next Generation Sequencing
  • 7.5.1. Whole Exome Sequencing
  • 7.5.2. Whole Genome Sequencing
• 7.6. PCR - Based Testing
• 7.7. Sanger Sequencing

8. Rare Disease Genetic Testing Market, by Specialty

• 8.1. Introduction
• 8.2. Biochemical Genetic Tests
• 8.3. Chromosomal Genetic Tests
• 8.4. Molecular Genetic Tests

9. Rare Disease Genetic Testing Market, by End-User

• 9.1. Introduction
• 9.2. Diagnostic Laboratories
• 9.3. Hospitals & Clinics
• 9.4. Research Laboratories & CROs

10. Americas Rare Disease Genetic Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Rare Disease Genetic Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Rare Disease Genetic Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Burjeel Holdings To Launch Rare Disease Research & Development Project 'Nader' In Partnership With US-Based Bridgebio Pharma
  • 13.3.2. NIH Launches USD 140 Million Effort To Investigate Genetic Variation In Normal Human Cells And Tissues
  • 13.3.3. CENTOGENE Launches NEW CentoGenome, A Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases

Companies Mentioned

• 1. Laboratory Corporation Of America Holdings
• 2. Biora Therapeutics, Inc.
• 3. 3billion, Inc.
• 4. Caris Life Sciences
• 5. Ambry Genetics Corporation
• 6. OPKO Health, Inc.
• 7. Color Health, Inc.
• 8. Quest Diagnostics Incorporated
• 9. Nonacus Limited
• 10. Integrated DNA Technologies, Inc. by Danaher Corporation
• 11. Myriad Genetics, Inc.
• 12. Blueprint Genetics Oy
• 13. PerkinElmer Inc.
• 14. Macrogen, Inc.
• 15. F. Hoffmann-La Roche Ltd.
• 16. Variantyx, Inc.
• 17. Centogene N.V.
• 18. Fulgent Genetics, Inc.
• 19. Genomelink, Inc.
• 20. Illumina, Inc.
• 21. GeneDx, LLC
• 22. Invitae Corporation
• 23. Sanofi S.A.
• 24. Helix OpCo, LLC
• 25. Arup Laboratories
• 26. The Cooper Companies, Inc.
• 27. QIAGEN N.V.
• 28. Realm IDX, Inc.
• 29. Baylor Genetics
• 30. Thermo Fisher Scientific Inc.